“In an era dominated by artificial intelligence, the trial provides meaningful support for a less-invasive physiology-guided strategy that may simplify decision making in treating the majority of patients with stable or unstable intermediate coronary lesions.”
Yiannis S. Chatzizisis (2026) studied this question.